Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Moprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 0.72 |
| ▸ | ADRB1 known ✓ | P08588 | 11/20 | 0.72 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.71 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.68 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.68 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.68 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.68 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.68 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.68 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.66 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.66 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.66 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.66 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.66 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.66 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.66 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.66 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.66 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levomoprolol SCHEMBL9120389 | 1.00 | ADRB2 (0.72) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Moprolol SCHEMBL30002163 | 0.98 | ADRB2 (0.74) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Moprolol SCHEMBL30910938 | 0.98 | ADRB2 (0.74) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Levomoprolol SCHEMBL80725 | 0.98 | ADRB2 (0.74) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Moprolol SCHEMBL80724 | 0.98 | ADRB2 (0.74) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Moprolol SCHEMBL1649455 | 0.95 | ADRB2 (0.70) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL11874444 | 0.94 | ADRB2 (0.80) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| SCHEMBL11868102 | 0.92 | ADRB2 (0.82) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| SCHEMBL10735720 | 0.88 | ADRB2 (0.76) | ADRB2ADRB1ADRB3HTR2ACYP1A2 | |
| Hydrochloric Acid SCHEMBL11221510 | 0.87 | CYP2D6 (0.72) | ADRB2ADRB1ADRB3HTR2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0015418-B1 | PROCESS FOR THE SEPARATION OF THE TWO OPTICAL ISOMERS OF 1-(O-METHOXYPHENOXY)-3-ISOPROPYLAMINO-PROPAN-2-OL, OPTICAL ISOMERS OBTAINED THEREBY AND PHARMACEUTICAL COMPOSITIONS OF THE LEVOROTATORY ANTIPODE THEREOF | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1982-07-21 | — | — | EP | claimed |
| EP-0015418-A1 | Process for the separation of the two optical isomers of 1-(o-methoxyphenoxy)-3-isopropylamino-propan-2-ol, optical isomers obtained thereby and pharmaceutical compositions of the levorotatory antipode thereof | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1980-09-17 | — | — | EP | claimed |
| WO-1995020568-A1 | PHARMACEUTICAL PRODUCT COMPRISING A SALICYLATE OF AN ESTERIFIABLE BETA-BLOCKER | CAL INTERNATIONAL LIMITED (IE) | 1995-08-03 | — | — | WO | disclosed |
| US-4849530-A | Process for the preparation of crystalline salts or aryloxy-propanolamines | RORER PHARMACEUTICAL CORPORATION (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0229947-A1 | Novel crystalline salts of aryloxy-propanolamines, their preparation and their use | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4683245-A | SIDE EFFECT REDUCTION | SIMES S.P.A. SOCIETA ITALIANA MEDICINALI E SINTETICI (IT) | 1987-07-28 | — | — | US | disclosed |
| EP-0015418-B1 | PROCESS FOR THE SEPARATION OF THE TWO OPTICAL ISOMERS OF 1-(O-METHOXYPHENOXY)-3-ISOPROPYLAMINO-PROPAN-2-OL, OPTICAL ISOMERS OBTAINED THEREBY AND PHARMACEUTICAL COMPOSITIONS OF THE LEVOROTATORY ANTIPODE THEREOF | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1982-07-21 | — | — | EP | disclosed |
| EP-0015418-A1 | Process for the separation of the two optical isomers of 1-(o-methoxyphenoxy)-3-isopropylamino-propan-2-ol, optical isomers obtained thereby and pharmaceutical compositions of the levorotatory antipode thereof | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1980-09-17 | — | — | EP | disclosed |
| US-4190654-A | Pharmaceutical composition comprising anxiolytic drugs and beta-adrenergic receptor blocking agents | Simes Societa Italiana Medicinali e Sintatici S.p.A. (IT) | 1980-02-26 | — | — | US | disclosed |
| US-3911136-A | 1-(O-METHOXY-PHENOXY)-3-ISOPROPYL-AMINO-PROPANE-2-OL HCl and nitroglycerine coronary insufficiency composition | ZAFIN S.A. A LUXEMBURGIAN COMPANY (LU) | 1975-10-07 | — | — | US | disclosed |